Provided are pharmaceutical compositions comprising (1R,55)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form. The compositions are formulated for providing a sustained release of enantiomerically pure (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.O)]hexane. The compositions are substantially free of the other (—) enantiomer of the compound.

Provided are pharmaceutical compositions comprising (1R,55)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form. The compositions are formulated for providing a sustained release of enantiomerically pure (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.O)]hexane. The compositions are substantially free of the other (—) enantiomer of the compound.

Provided are pharmaceutical compositions comprising (1R,55)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form. The compositions are formulated for providing a sustained release of enantiomerically pure (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.O)]hexane. The compositions are substantially free of the other (—) enantiomer of the compound.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

The present invention provides a novel use of a compound having a plasminogen activator inhibitor-1 (PAI-1) inhibitory effect. Specifically, a compound having a PAI-1 inhibitory effect is used as an intranostimulator, an immune checkpoint inhibitor, an inhibitor for exacerbation of tumor cells caused by PD-L1, or an enhancer of immunotherapy for tumors, based on the inhibitory effect of the compound on expression induction of immune checkpoint molecules.

The present invention provides a novel use of a compound having a plasminogen activator inhibitor-1 (PAI-1) inhibitory effect. Specifically, a compound having a PAI-1 inhibitory effect is used as an intranostimulator, an immune checkpoint inhibitor, an inhibitor for exacerbation of tumor cells caused by PD-L1, or an enhancer of immunotherapy for tumors, based on the inhibitory effect of the compound on expression induction of immune checkpoint molecules.

The present invention relates to the process and therapeutic use of endocannabinoid-targeting novel prodrugs in a delivery system. In particular, the present invention relates to prodrugs of endocannabinoid system-targeting molecules, as cannabidiol (CBD), cannabigerol (CBG), tetrahydrocannabinol (THC), and cannabichromene (CBC) for oral, transmucosal, transdermal, and parenteral administration, and methods and using the same as therapeutics.

The present invention relates to the process and therapeutic use of endocannabinoid-targeting novel prodrugs in a delivery system. In particular, the present invention relates to prodrugs of endocannabinoid system-targeting molecules, as cannabidiol (CBD), cannabigerol (CBG), tetrahydrocannabinol (THC), and cannabichromene (CBC) for oral, transmucosal, transdermal, and parenteral administration, and methods and using the same as therapeutics.

The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.